Total Payments
$237,864
2024 Payments
$32,187
Companies
30
Transactions
274
Medicare Patients
1,013
Medicare Billing
$149,849
Payment Breakdown by Category
Other$189,548 (79.7%)
Travel$21,554 (9.1%)
Consulting$19,629 (8.3%)
Food & Beverage$6,823 (2.9%)
Education$310.98 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $189,548 | 81 | 79.7% |
| Travel and Lodging | $21,554 | 51 | 9.1% |
| Consulting Fee | $19,629 | 12 | 8.3% |
| Food and Beverage | $6,823 | 125 | 2.9% |
| Education | $310.98 | 5 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Seagen Inc. | $111,576 | 96 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $58,892 | 52 | $0 (2024) |
| Astellas Pharma US Inc | $31,143 | 28 | $0 (2024) |
| Merck Sharp & Dohme LLC | $20,675 | 32 | $0 (2024) |
| PFIZER INC. | $7,389 | 12 | $0 (2024) |
| Eisai Inc. | $2,339 | 4 | $0 (2023) |
| GENZYME CORPORATION | $1,824 | 1 | $0 (2021) |
| Array BioPharma Inc. | $1,800 | 1 | $0 (2019) |
| ABBVIE INC. | $578.90 | 7 | $0 (2024) |
| Incyte Corporation | $335.00 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32,187 | 41 | AstraZeneca Pharmaceuticals LP ($16,676) |
| 2023 | $65,657 | 62 | Seagen Inc. ($33,621) |
| 2022 | $44,104 | 47 | Seagen Inc. ($24,219) |
| 2021 | $57,837 | 54 | Seagen Inc. ($42,588) |
| 2020 | $16,713 | 18 | Seagen Inc. ($11,148) |
| 2019 | $19,431 | 23 | Merck Sharp & Dohme Corporation ($17,631) |
| 2018 | $1,320 | 23 | Incyte Corporation ($335.00) |
| 2017 | $615.41 | 6 | Abbvie, Inc. ($347.95) |
All Payment Transactions
274 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Janssen Scientific Affairs, LLC | ERLEADA (Drug), AKEEGA, PIPELINE | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: Oncology | ||||||
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,640.00 | General |
| Category: Oncology | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.77 | General |
| Category: Oncology | ||||||
| 12/02/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | Genentech USA, Inc. | Tecentriq (Biological), Tecentriq Hybreza | Food and Beverage | In-kind items and services | $13.65 | General |
| Category: BioOncology | ||||||
| 11/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $14.56 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,640.00 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $15.47 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Astellas Pharma US Inc | Padcev (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $22.49 | General |
| Category: Oncology | ||||||
| 10/21/2024 | Astellas Pharma Global Development | Padcev (Drug) | Food and Beverage | In-kind items and services | $21.77 | General |
| Category: Oncology | ||||||
| 10/17/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,280.00 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $64.96 | General |
| 10/07/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: Oncology | ||||||
| 10/02/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $120.53 | General |
| Category: Oncology | ||||||
| 09/17/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $14.03 | General |
| Category: Oncology | ||||||
| 09/16/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: Oncology | ||||||
| 09/13/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $15.71 | General |
| Category: Oncology | ||||||
| 08/26/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $95.84 | General |
| 08/03/2024 | Astellas Pharma US Inc | Padcev (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,110.00 | General |
| Category: Oncology | ||||||
| 08/03/2024 | Astellas Pharma US Inc | Padcev (Drug) | Travel and Lodging | Cash or cash equivalent | $471.35 | General |
| Category: Oncology | ||||||
| 08/03/2024 | Astellas Pharma US Inc | Padcev (Drug) | Travel and Lodging | Cash or cash equivalent | $431.65 | General |
| Category: Oncology | ||||||
| 08/03/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $27.05 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 256 | 409 | $65,870 | $28,600 |
| 2022 | 4 | 236 | 383 | $79,994 | $35,439 |
| 2021 | 5 | 242 | 507 | $105,062 | $46,788 |
| 2020 | 8 | 279 | 562 | $103,831 | $39,022 |
Total Patients
1,013
Total Services
1,861
Medicare Billing
$149,849
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 82 | 149 | $23,542 | $10,378 | 44.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 65 | 95 | $15,010 | $6,435 | 42.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 22 | 32 | $7,616 | $3,448 | 45.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 20 | 27 | $6,426 | $2,808 | 43.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 26 | $4,290 | $1,583 | 36.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 21 | 32 | $3,200 | $1,432 | 44.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 22 | 31 | $3,100 | $1,351 | 43.6% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 13 | 17 | $2,686 | $1,166 | 43.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 70 | 142 | $33,796 | $15,418 | 45.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 53 | 91 | $14,378 | $6,279 | 43.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 40 | 59 | $14,042 | $6,205 | 44.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $6,086 | $2,269 | 37.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 18 | 25 | $3,950 | $1,760 | 44.6% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 18 | 23 | $3,634 | $1,755 | 48.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 20 | 26 | $4,108 | $1,753 | 42.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 60 | 158 | $37,604 | $17,819 | 47.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 38 | 74 | $17,612 | $8,185 | 46.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 38 | 98 | $15,484 | $7,100 | 45.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 24 | 51 | $10,914 | $4,131 | 37.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 28 | 50 | $7,900 | $3,464 | 43.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 22 | 33 | $5,214 | $2,206 | 42.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 12 | 15 | $5,910 | $2,199 | 37.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 20 | 28 | $4,424 | $1,684 | 38.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 38 | 88 | $20,944 | $7,677 | 36.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 43 | 87 | $20,706 | $7,428 | 35.9% |
About Dr. Prateek Mendiratta, M.D
Dr. Prateek Mendiratta, M.D is a Medical Oncology healthcare provider based in Beachwood, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1104960525.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Prateek Mendiratta, M.D has received a total of $237,864 in payments from pharmaceutical and medical device companies, with $32,187 received in 2024. These payments were reported across 274 transactions from 30 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($189,548).
As a Medicare-enrolled provider, Mendiratta has provided services to 1,013 Medicare beneficiaries, totaling 1,861 services with total Medicare billing of $149,849. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology, Hematology & Oncology
- Location Beachwood, OH
- Active Since 02/18/2007
- Last Updated 10/04/2011
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1104960525
Products in Payments
- PADCEV (Biological) $117,011
- LYNPARZA (Drug) $58,760
- Padcev (Drug) $20,674
- KEYTRUDA (Biological) $20,459
- PADCEV (Drug) $10,498
- Lenvima (Drug) $2,339
- JEVTANA (Drug) $1,824
- Braftovi (Drug) $1,800
- TECENTRIQ (Biological) $189.25
- PLUVICTO (Drug) $132.43
- Xofigo (Drug) $116.14
- BAVENCIO (Drug) $102.46
- ERLEADA (Drug) $94.45
- Axumin (Drug) $91.60
- OPDIVO (Biological) $50.78
- XTANDI (Drug) $49.01
- ORGOVYX (Drug) $48.98
- ELIGARD (Drug) $42.00
- Stivarga (Drug) $39.62
- LUMAKRAS (Drug) $34.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.